CLAIMS

1. Use of a pharmaceutical combination in the manufacture of a medicament for the treatment of a type 2 diabetes mellitus patient, said pharmaceutical combination comprising

   (a) a pharmaceutical formulation comprising

      (i) lixisenatide or/and a pharmaceutically acceptable salt thereof in a concentration of 33 µg/mL, 50 µg/mL or 100 µg/mL, and

      (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof in a concentration of 100 U/mL,

   (b) an SGLT2 inhibitor, or/and a pharmaceutically acceptable salt thereof, and

   (c) metformin or/and pharmaceutically acceptable salt thereof,

   wherein the type 2 diabetes mellitus to be treated is not adequately controlled with

   (i) the SGLT2 inhibitor alone;

   (ii) an SGLT2 inhibitor and an oral anti-diabetic alone;

   (iii) the SGLT2 inhibitor and metformin alone, or with an SGLT2 inhibitor and a GLP-1 receptor agonist alone; and/or

   (iv) the SGLT2 inhibitor, metformin and a GLP-1 receptor agonist alone.

2. The pharmaceutical combination for use according to claim 1, wherein the SGLT2 inhibitor is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin and ertugliflozin.

3. The use according to any one of the preceding claims, wherein the GLP-1 receptor agonist is selected from lixisenatide, exenatide, dulaglutide, and liraglutide.

4. The use according to any one of the preceding claims, wherein the patient to be treated is obese.